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Gel tests are now available for the determination of immuno-
globulin classes and subclasses and complement fractions coating
RBCs. These tests simplified serologic characterization of autoanti-
bodies in various autoimmune diseases. The aim of this study was
to evaluate the use of gel cards in the serologic characterization of
autoantibody with regard to the immunoglobulin classes, comple-
ment fractions, and IgG subclasses, and the influence of these
characteristics on hemolysis. Gel cards were used to characterize
the RBC-bound autoantibodies in 66 DAT-positive patients.
Hematologic and biochemical parameters such as Hb, reticulocyte
count, serum bilirubin, and serum LDH were obtained from the
patient files. Of the 49 patients carrying IgG on their RBCs, 21
(42.8%) were suffering from connective tissue disorders and
another 16 patients (32.7%) had autoimmune hemolytic anemia. A
total of 19 of these 49 patients had evidence of hemolysis. Thirteen
of the 17 patients (76.5%) whose RBCs were coated with more than
one type of immunoglobulin and complement were experiencing
hemolysis (p < 0.05). Seventy-five percent (21 of 28) of patients
having IgG1, IgG3, or both on their RBCs showed hemolysis (p <
0.05). Thus, it is important to serologically characterize
autoantibodies in autoimmune disorders to effectively predict the
prognosis and disease outcome. This characterization can be
performed effectively with the gel test,which can be introduced in
blood centers as a replacement to the conventional tube technique.
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Autoimmune hemolytic diseases are characterized
by the formation of antibody against the individual’s
own RBCs.1 These autoantibodies,detected by the DAT,
at times cause hemolysis that adds to the increased risk
of morbidity and mortality of patients. The patho-
genicity of autoantibodies depends on several factors,of
which classes, subclasses, and titer of autoantibody and
the associated complement activation are of serologic
importance.2–5 Although the conventional tube
technique (CTT) is still the gold standard for DAT
evaluation, the use of gel technology (GT) is growing
gradually because of its simplicity, reproducibility,
avoidance of RBC washing, and ease of detecting
immunoglobulin classes and subclasses and comple-
ment fractions.6,7 GT has been found to be as sensitive
as flow cytometry for the detection of RBC–bound IgG.8
GT uses the gel filtration media impregnated with
polyspecific or monospecific anti-human globulin
(AHG) reagents to bring about agglutination.9 Gel cards
are now available to assess the strength of the DAT
(DAT IgG dilution cards) or to determine the immuno-
globulin subclasses of antibodies. These cards have
simplified the serologic characterization of autoanti-
body. Moreover, with the use of these cards clinical
hematologists may not have to depend on immuno-
hematology laboratories for the evaluation of their
patients as these tests can be performed without
extensive infrastructure and trained manpower.
The purpose of this study was to evaluate DAT-
positive autoimmune diseases using special gel cards
from DiaMed AG, Cressier sur Morat, Switzerland.
Note: The special gel cards used in this study may
not be available to all gel users as they have not been
approved by the FDA for the U.S.market.
Materials and Methods
The study was carried out at the immunohematol-
ogy laboratory of the Department of Transfusion
Medicine, Sanjay Gandhi Postgraduate Institute of
Medical Sciences, Lucknow, India, from January 2004 to
June 2006. After seeking approval of the institute
research committee and consent of the patients,
EDTA blood samples from 164 patients clinically
suspected of suffering from various autoimmune
disorders were evaluated for DAT profile and
autoantibody characterization.
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Fifty microliters of a 1% RBC suspension in LISS
was added to each microtube of the labeled ID cards
(LISS-Coombs card, DiaMed) containing gel matrix
impregnated with polyspecific AHG containing anti-
IgG and anti-C3d. The cards were then centrifuged at
70 g for 10 minutes in the dedicated DiaMed ID
centrifuge (DiaMed). The DAT reactions were graded
according to the manufacturer’s instructions. A
discrete RBC button at the base of the column
indicated a negative reaction. Appropriate controls
were tested along with the samples following the
manufacturer’s instructions.
Samples that tested positive by the DAT with
polyspecific AHG were further tested for immuno-
globulin class using gel cards containing monospecific
AHG (anti-IgG, anti-IgM, anti-IgA, anti-C3c, and anti-C3d).
If the antibody detected was IgG in nature, gel cards
impregnated with monospecific anti-IgG1 and anti-IgG3
were used to determine the IgG subclass. Both IgG1 and
IgG3 may activate complement, so this test algorithm
was intended to estimate the risk and severity of hemo-
lysis for the underlying disease. The strength of the DAT
was determined using a gel card with anti-IgG in serial
dilutions (1:1, 1:10, 1:30, 1:100, 1:300, and 1:1000). This
test not only indicates the clinical importance of a DAT-
positive result but also helps in assessing the relative
amount of IgG sensitizing the RBCs and further helps in
estimating the risk of hemolysis in an autoimmune
disease.10,11 An anti-IgG titer of more than or equal to 300
was considered clinically relevant in accordance with
the guidelines furnished by the manufacturer.10 In all the
techniques, the findings of the agglutination reactions
were graded as 4+, 3+, 2+, 1+, weak, and negative and
documented accordingly.
Four variables were used to determine hemolysis: a
decrease in Hb (< 9 g/dL), an increase in reticulocytes
(> 2 %), a bilirubin level of more than 2 mg/dL, and an
LDH concentration of more than 500 IU.
Statistical analysis
A two-tailed Student’s t test using computer
software (SPSS, Chicago, IL) was used to analyze the
relationship between IgG classes and subclass with
hemolysis. A probability value of less than 0.05 was
considered as significant.
Results
Of the 164 samples evaluated, 66 were reactive by
the polyspecific DAT using the GT. The median age of
these DAT-positive patients was 31 years,with a female
predilection (M/F = 1:3.5). The majority (88%) of them
had autoantibodies reactive at 37°C. Of the 66
patients, 24 (36.4%) were clinically and serologically
diagnosed with autoimmune hemolytic anemia (AIHA),
20 (30.3%) with systemic lupus erythematosus (SLE),
and 6 (9.1%) with autoimmune hepatitis; the rest were
diagnosed as having various other autoimmune
diseases such as rheumatoid arthritis (RA; n = 2),
glomerulonephritis (n = 3), Hashimoto’s thyroiditis (n
= 2), inflammatory myositis (n = 1),pancreatitis (n = 1),
or lymphoproliferative disorders such as leukemias and
lymphomas (n = 7).
Table 1 depicts the prevalence of different
immunoglobulin classes and complement fractions in
the various autoimmune diseases we encountered. In
74.2 percent (49 of 66) of the patients, IgG alone was
present (p < 0.05). Of these 49 patients, 21 (42.8%)
were suffering from connective tissue disorders such
as SLE, RA, inflammatory myositis, etc., and another 16
patients (32.7%) had AIHA. Multiple immunoglobulin
classes were detected in 16 patients, of which the
majority (50%) had AIHA. The RBCs of one 65-year-old
patient with Hodgkin’s lymphoma were found to be
coated with only C3c and C3d.
Association of immunoglobulin classes, IgG
subclasses, and complement fractions with clinical
hemolysis is shown in Table 2. Of the 49 patients with
RBCs coated with only IgG,19 (38.8%) had evidence of
hemolysis. Thirteen of the 17 patients (76.5%) having
multiple immunoglobulin classes or complement
or both were experiencing hemolysis (p < 0.05).
Table 1. Immunoglobulin class and complement fractions in
autoimmune diseases (N = 66)
Type of AIHA CTD AIH LPD Others
autoantibody (N = 24) (N = 23) (N = 6) (N = 7) (N = 6)
IgG (n = 49) 16 21 3 3 6
IgG + IgM (n = 2) – 1 – 1 –
IgG + IgA (n = 1) 1 – – – –
IgG + C3 (n = 7) 3 1 2 1 –
IgG + IgA + C3 (n = 1) 1 – – – –
IgG + IgM + IgA + C3 3 – 1 1 –
(n = 5)
C3c + C3d (n = 1) – – – 1 –
AIHA = autoimmune hemolytic anemia.
Connective tissue disorders (CTD) include systemic lupus erythematosus, rheumatoid
arthritis, and inflammatory myositis.
AIH = autoimmune hepatitis.
Lymphoproliferative disorders (LPD) include leukemias and lymphomas.
Others include glomerulonephritis, Hashimoto’s thyroiditis, and pancreatitis.
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Subclasses of IgG such as IgG1, IgG3, or both were
detected in 28 patients, of whom 21 (75%) were
associated with hemolysis compared with only 27
percent of patients experiencing hemolysis when
these were not demonstrated on the RBCs (p < 0.05).
Of the 21 patients exhibiting hemolysis as a result
of IgG1, IgG3,or both,12 had a titer more than or equal
to 300. However, the values of the hemolysis deter-
minants in these patients were not statistically
significant when compared with an autoantibody titer
of less than 300 causing hemolysis in the other 9
patients.
Discussion
The advent of GT has tremendously improved RBC
serologic investigations and has replaced the CTT in
many blood centers.6,9 Introduction of specialized gel
cards, such as monospecific immunoglobulin cards, IgG
subclass cards, and IgG dilution cards, have made it
possible to characterize RBC-bound antibodies in a
simplified and rapid way. Detailed investigation of
these autoantibodies helps in predicting the severity of
hemolysis and disease outcome and in planning
therapy in autoimmune disorders.11
We determined serologic characteristics of
autoantibodies in patients with autoimmune diseases
with regard to immunoglobulin class, subclass, and titer
of IgG using specialized gel cards provided by DiaMed,
Switzerland. Of the 49 patients having IgG as the sole
autoantibody, 21 (42.8%) had connective tissue
disorders and another 16 patients (32.7%) had AIHA.
Multiple immunoglobulin classes were detected in 16
patients, of which the majority (50%) had AIHA.
Similarly, Sokol et al.12 and Issitt et al.13 found 63
percent and 43.7 percent, respectively, of their AIHA
patients had IgG as the sole autoantibody. In a study of
samples from different autoimmune patients, IgG and
C3d were seen in 43.7 percent, IgG only in 50 percent,
and C3d sensitization in 6.3 percent of patients.14 All of
these results approximated to the findings of the
present study.
We observed association of class and subclass of
autoantibody with clinical hemolysis. In 74.2 percent
(49 of 66) of our patients, IgG was the solitary
immunoglobulin and of these, 38.8 percent had in vivo
hemolysis (Table 2). However, more than 76 percent
(13 of 17) of those patients whose RBCs were coated
with multiple immunoglobluins or complement or
both experienced hemolysis. Similar observations
were made by Sokol et al.15 and Fabijanska-Mitek et
al.,16 who reported that RBCs coated with multiple
immunoglobulins undergo hemolysis more readily
compared with RBCs coated with IgG alone. IgG
molecules cause hemolysis mainly by complement
activation17; however, the presence of regulatory RBC
proteins (DAF or CD55, MIRL or CD59) restrict such
activation, and clinical hemolysis with IgG alone is less
common. Contrary to this, multiple immunoglobulins
readily activate the classic complement pathway and
cause significant hemolysis.
We found that in vivo hemolysis was more
pronounced when RBCs were coated with IgG1, IgG3,
or both (Table 2). Sokol et al.15 observed IgG1 as the
predominant IgG subclass in 98 percent of the total
cases. In contrast to this, only 31.8 percent (21 of 66)
of our patients had IgG1 alone bound to their RBCs,
and this difference could be attributed to different
methods of detection. The gel cards used in the
present study were impregnated with only serially
diluted anti-IgG1 and anti-IgG3,so the presence of IgG2
and IgG4 could not be ruled out.
The strength of the DAT was determined in all
patients using IgG dilution gel cards (DiaMed).
However, no correlation of DAT titer with in vivo
hemolysis was observed, although an increased value
(> 300) was associated with abnormal hematologic and
biochemical values.
The results of our study demonstrate that GT is
effective for the characterization of RBC-bound
Table 2. Correlation of IgG classes, subclasses, and complement fractions
of autoantibodies with hemolysis in autoimmune disease
(N = 66)
Hemolysis No hemolysis
Antibody type n (%) n (%)
Ig class / complement (N = 66) 32 (48.5) 34 (51.5)
IgG (n = 49) 19 (38.8) 30 (61.2)
IgG + IgM (n = 2) 1 (50) 1 (50)
IgG + IgA (n = 1) 1 (100) –
IgG + C3 (n = 7) 5 (71.4) 2 (28.6)
IgG + IgA + C3 (n = 1) 1 (100) –
IgG + IgA + IgM + C3 (n = 5) 5 (100) –
C3 (n = 1) – 1 (100)
IgG/C3 subclass (N = 66) 32 (48.5) 34 (51.5)
IgG1 (n = 21) 14 (66.7) 7 (33.3)
IgG3 (n = 2) 2 (100) –
IgG1 + IgG3 (n = 5) 5 (100) –
C3c/C3d (n = 1) 1 (100) –
No IgG1/IgG3 (n = 37) 10 (27) 27 (73)
p < 0.05 comparing IgG1, IgG3, or both vs. no detectable IgG1 or IgG3 and their
association with hemolysis.
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autoantibodies with regard to their classes, subclasses,
and titer and its correlation with in vivo hemolysis in
autoimmune diseases. Dittmar et al.8 in 2001 reported
that laboratories should not rely on a single method to
characterize autoantibodies, especially in conditions
with clinical evidence of hemolysis. Considering the
various advantages of GT and its recent developments,
it would be prudent to introduce the technique in
blood centers either as a replacement or as an
additional parallel assay to the CTT in the serologic
characterization of autoimmune hemolysis. In addition,
the clinicians can become “self-reliant” with regard to
complete serologic evaluation of patients with
autoimmune diseases.
References
1. Sokol RJ, Booker DJ, Stamps R. Investigation of
patients with autoimmune hemolytic anemia and
provision of blood for transfusion. J Clin Pathol
1995;48:602–10.
2. Petz LD, Garratty G. Immune hemolytic anemias.
Philadelphia: Churchill Livingstone, 2004.
3. Sokol RJ,Hewitt S,Booker DJ,Bailey A.Erythrocyte
autoantibodies, subclasses of IgG and auto-
immune hemolysis.Autoimmunity 1990;6:99–104.
4. Zupanska B,Brojer E,McIntosh J,Seyfrid H,Howell
P. Correlation of monocyte monolayer assay
results, number of erythrocyte-bound IgG
molecules and of IgG subclass composition in the
study of red cell alloantibodies other than D.Vox
Sang 1990;58:276–80.
5. Wikman A, Axdorph U, Gryfelt G, Gustafsson L,
Bjorkholm M, Lundahl J. Characterization of red
cell autoantibodies in consecutive DAT-positive
patient with relation to in vivo hemolysis. Ann
Hematol 2005;84:150–8.
6. LapierreY,Rigar D,Adam J,et al.The gel test: a new
way to detect red cell antigen antibody reactions.
Transfusion 1990;30:109–13.
7. Greco VA, Byrne KM, Procter JL, Stroncek DF.
Detection of antibodies in acid eluates with the
gel microcolumn assay. Transfusion 2002;42:
698–701.
8. Dittmar K, Procter JL, Cipolone K, Njorage JM,
Miller J, Stroncek DF. Comparison of DATs using
traditional tube agglutination to gel column and
affinity column procedures. Transfusion 2001;41:
1258–62.
9. Reis KJ,Chachowski R,Cupido A,Davies D, Jakway
J, Stecavage TM.Column agglutination technology:
the antiglobulin test.Transfusion 1993;33:639–43.
10. Schmitz N, Djibey I, Kretschmer V, et al. Assess-
ment of red cell autoantibodies in autoimmune
hemolytic anemia of warm type by a radioactive
anti-IgG test.Vox Sang 1981;41:224-230.
11. Wheeler CA,Calhoun L,Blackall DP.Warm reactive
autoantibodies: clinical and serological correla-
tions.Am J Clin Pathol 2004;122:680–5.
12. Sokol RJ, Booker DJ, Stamps R. The pathology of
autoimmune hemolytic anemia. J Clin Pathol
1992;45:1047–52.
13. Issitt PD, Pavone BG, Goldfinger D, et al. Anti Wrb
and other autoantibodies responsible for positive
direct antiglobulin tests in 150 individuals. Br J
Haematol 1976;34:5–8.
14. Stec N,Shirey RS,Smith B,Kickler TS,Ness PM.The
efficacy of performing red cell elution studies in
the pretransfusion testing of patients with posi-
tive direct antiglobulin tests.Transfusion 1986;26:
225–6.
15. Sokol RJ, Hewitt S, Booker DJ, Bailey A. Red cell
autoantibodies, multiple immunoglobulin classes,
and autoimmune hemolysis. Transfusion 1990;30:
714–7.
16. Fabijanska-Mitek J,Namirska-Krzton H, Seyfried H.
The value of gel test and ELAT in autoimmune
hemolytic anemia. Clin Lab Haematol 1995;17:
311–6.
17. Duffy TP. Autoimmune hemolytic anemia and
paroxysmal nocturnal hemoglobinuria. In: Simon
TL, Dzik WH, Synder EL, Stowell CP, Strauss RG,
eds.Rossi’s principles of transfusion medicine.3rd
ed. Philadelphia: Lippincott Williams & Wilkins,
2002. pp 345–366.
Sudipta Sekhar Das, MBBS, MD, and Rajendra K.
Chaudhary, MD, DNB (corresponding author),
Department of Transfusion Medicine, Sanjay Gandhi
Postgraduate Institute of Medical Sciences, Raibareli
Road, Lucknow 226014, India.
S.S. DAS AND R.K. CHAUDHARY
